NZ330596A
(en)
*
|
1998-06-05 |
2001-02-23 |
Dec Res |
Intravaginal devices allowing for increased uptake of active ingredients
|
US7588793B1
(en)
|
1998-06-05 |
2009-09-15 |
Cadbury Adams Usa, Llc |
Enhanced flavoring compositions containing N-ethyl-p-menthane-3-carboxamide and method of making and using same
|
AP1414A
(en)
|
1998-12-24 |
2005-06-13 |
Janssen Pharmaceutica Nv |
Controlled release galantamine composition.
|
ES2306646T3
(es)
*
|
1999-02-09 |
2008-11-16 |
Pfizer Products Inc. |
Composiciones de farmacos basicos con biodisponibilidad incrementada.
|
AU3900300A
(en)
|
1999-03-24 |
2000-10-09 |
Fmc Corporation |
Improved aqueous solubility pharmaceutical formulations
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
EP1109806B8
(en)
*
|
1999-07-01 |
2003-10-29 |
Italfarmaco S.p.A. |
Complexes of paroxetine, with cyclodextrins or cyclodextrin derivates
|
WO2001001955A1
(en)
*
|
1999-07-02 |
2001-01-11 |
Janssen Pharmaceutica N.V. |
Nasal formulation of an antifungal
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
US6835717B2
(en)
|
2000-03-08 |
2004-12-28 |
The Johns Hopkins University School Of Medicine |
β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
|
DE60136926D1
(de)
|
2000-05-02 |
2009-01-22 |
Theravance Inc |
Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
JP3693957B2
(ja)
|
2000-05-26 |
2005-09-14 |
ファイザー・インク |
療法において有用なトロパン誘導体
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
CN1322850C
(zh)
*
|
2000-06-02 |
2007-06-27 |
沈阳药科大学 |
盐酸尼卡地平粉针剂及其制备方法
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
GB0015239D0
(en)
*
|
2000-06-21 |
2000-08-16 |
Biochemie Gmbh |
Organic compounds
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
PE20020300A1
(es)
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
EP1343372A2
(en)
|
2000-12-21 |
2003-09-17 |
Nektar Therapeutics |
Pulmonary delivery of polyene antifungal agents
|
US6579898B2
(en)
|
2001-03-01 |
2003-06-17 |
Pfizer Inc. |
Compositions having improved bioavailability
|
KR100569324B1
(ko)
|
2001-04-10 |
2006-04-07 |
화이자 인코포레이티드 |
Hiv 치료용 피라졸 유도체
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
FR2827516B1
(fr)
*
|
2001-07-19 |
2003-09-19 |
Servier Lab |
Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
CN100384865C
(zh)
*
|
2001-11-02 |
2008-04-30 |
嵌入治疗公司 |
用于rna干扰的治疗用途的方法及组合物
|
CA2363376A1
(en)
*
|
2001-11-16 |
2003-05-16 |
Bernard Charles Sherman |
Solid pharmaceutical compositions for oral administration comprising itraconazole
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
EA008939B1
(ru)
|
2002-02-11 |
2007-10-26 |
Пфайзер Инк. |
Производные никотинамида, полезные в качестве ингибиторов pde4
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
US8128957B1
(en)
|
2002-02-21 |
2012-03-06 |
Valeant International (Barbados) Srl |
Modified release compositions of at least one form of tramadol
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
WO2004022100A1
(fr)
*
|
2002-08-15 |
2004-03-18 |
Yunqing Liu |
Formulation nanopharmaceutique et son procede de preparation
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
AU2003275329B2
(en)
*
|
2002-09-13 |
2008-04-03 |
Cydex Pharmaceuticals, Inc. |
Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
KR20070091049A
(ko)
|
2002-12-13 |
2007-09-06 |
워너-램버트 캄파니 엘엘씨 |
하부요로증상을 치료하기 위한 알파-2-델타 리간드
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
US7993654B2
(en)
*
|
2002-12-23 |
2011-08-09 |
Beiersdorf Ag |
Self-adhesive polymer matrix containing sea algae extract
|
DE10260873A1
(de)
|
2002-12-23 |
2004-07-15 |
Beiersdorf Ag |
Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
|
DE10260872B4
(de)
|
2002-12-23 |
2013-09-26 |
Beiersdorf Ag |
Verwendung von gelbildendem Polymer, Wasser, Alkohol und Meeresalgenextrakt zur Einstellung von Elastizität und Haftvermögen selbstklebender kosmetischer Polymermatrices
|
US20060177498A1
(en)
*
|
2003-01-22 |
2006-08-10 |
Ramaswami Bharatrajan |
Solid pharmaceutical composition comprising ramipril
|
MXPA05008718A
(es)
*
|
2003-02-17 |
2005-09-20 |
Sun Pharmaceutical Ind Ltd |
Una composicion de corticosteroide de dosis baja.
|
EP1460064A1
(en)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide derivatives useful as beta-2 agonists
|
MXPA05010330A
(es)
|
2003-03-28 |
2006-05-31 |
Ivax Corp |
Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa.
|
JP5256611B2
(ja)
|
2003-03-28 |
2013-08-07 |
アレス トレーディング ソシエテ アノニム |
クラドリビンの経口製剤
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
DE10338544B4
(de)
*
|
2003-08-19 |
2017-08-31 |
Janssen Pharmaceutica N.V. |
Buccale Formulierungen des Galanthamins und deren Anwendungen
|
US20070190129A1
(en)
*
|
2003-09-02 |
2007-08-16 |
Pfizer Inc. |
Sustained release dosage forms of ziprasidone
|
MXPA06002550A
(es)
|
2003-09-03 |
2006-06-20 |
Pfizer |
Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4.
|
EP1663220B1
(en)
|
2003-09-03 |
2009-12-02 |
Glaxo Group Limited |
Novel process for the preparation of pleuromutilin derivatives
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6960300B2
(en)
*
|
2003-09-08 |
2005-11-01 |
Sami Labs Limited |
Process for preparing water soluble diterpenes and their applications
|
RU2320369C2
(ru)
|
2003-09-12 |
2008-03-27 |
Пфайзер Инк. |
Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
|
US7309790B2
(en)
|
2003-10-03 |
2007-12-18 |
Pfizer Inc |
Chemical compounds
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US8389031B2
(en)
|
2005-05-23 |
2013-03-05 |
Kraft Foods Global Brands Llc |
Coated delivery system for active components as part of an edible composition
|
US8591972B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for coated active components as part of an edible composition
|
US20050112236A1
(en)
|
2003-11-21 |
2005-05-26 |
Navroz Boghani |
Delivery system for active components as part of an edible composition having preselected tensile strength
|
US8597703B2
(en)
|
2005-05-23 |
2013-12-03 |
Kraft Foods Global Brands Llc |
Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
|
US8591973B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
|
AU2004292445B2
(en)
|
2003-11-21 |
2010-02-04 |
Zalicus Inc. |
Methods and reagents for the treatment of inflammatory disorders
|
US8389032B2
(en)
|
2005-05-23 |
2013-03-05 |
Kraft Foods Global Brands Llc |
Delivery system for active components as part of an edible composition having selected particle size
|
US9271904B2
(en)
|
2003-11-21 |
2016-03-01 |
Intercontinental Great Brands Llc |
Controlled release oral delivery systems
|
US8591968B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Edible composition including a delivery system for active components
|
US8591974B2
(en)
|
2003-11-21 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for two or more active components as part of an edible composition
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
RS50538B
(sr)
|
2004-01-22 |
2010-05-07 |
Pfizer Limited |
Sulfonamidni derivati namenjeni lečenju bolesti
|
GEP20094781B
(en)
|
2004-01-22 |
2009-09-25 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
US7687533B2
(en)
|
2004-03-18 |
2010-03-30 |
Pfizer Inc. |
N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides
|
AP2315A
(en)
|
2004-03-23 |
2011-11-04 |
Pfizer |
Formamide derivatives useful as adrenoceptor.
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
KR100479367B1
(ko)
*
|
2004-04-13 |
2005-03-29 |
(주) 에프디엘 |
이트라코나졸을 포함하는 경구투여용 항진균제 조성물
|
KR100943555B1
(ko)
|
2004-04-30 |
2010-02-22 |
워너-램버트 캄파니 엘엘씨 |
중추신경계 장애를 치료하기 위한 치환된 모르폴린 화합물
|
KR20070009671A
(ko)
*
|
2004-05-06 |
2007-01-18 |
사이덱스 인크 |
세르트랄린 및 술포알킬 에테르 시클로덱스트린을 함유하는맛 마스킹된 제제
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
EP1595881A1
(en)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
|
WO2005123718A2
(en)
|
2004-06-15 |
2005-12-29 |
Pfizer Japan Inc. |
Benzimidazolone carboxylic acid derivatives
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
US20050282895A1
(en)
*
|
2004-06-21 |
2005-12-22 |
Dosch Michael H |
Antimicrobial compositions and methods of use thereof
|
BRPI0514283A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Cadbury Adams Usa Llc |
composições para aquecimento e sistemas de liberação para as mesmas
|
EP1778686B9
(en)
|
2004-08-12 |
2009-07-08 |
Pfizer Limited |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
|
US7955630B2
(en)
*
|
2004-09-30 |
2011-06-07 |
Kraft Foods Global Brands Llc |
Thermally stable, high tensile strength encapsulated actives
|
US7727565B2
(en)
|
2004-08-25 |
2010-06-01 |
Cadbury Adams Usa Llc |
Liquid-filled chewing gum composition
|
US20060068058A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Cadbury Adams Usa Llc |
Thermally stable, high tensile strength encapsulation compositions for actives
|
DK1786785T3
(da)
|
2004-08-26 |
2010-05-31 |
Pfizer |
Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
|
CN1325054C
(zh)
*
|
2004-09-29 |
2007-07-11 |
南京师范大学 |
盐酸哌唑嗪的环糊精包合物及其制备方法
|
MX2007005290A
(es)
|
2004-11-02 |
2007-07-09 |
Pfizer |
Derivados de sulfonilbencimidazol.
|
GT200500317A
(es)
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
JP4335120B2
(ja)
|
2004-11-08 |
2009-09-30 |
カゴメ株式会社 |
混合飲料の製造方法
|
US9198448B2
(en)
*
|
2005-02-07 |
2015-12-01 |
Intercontinental Great Brands Llc |
Stable tooth whitening gum with reactive ingredients
|
US8703099B2
(en)
|
2005-02-24 |
2014-04-22 |
Dr Pharma Nova, Llc |
Registry method and control system for DEA schedule II-V medicines
|
KR100927915B1
(ko)
|
2005-03-17 |
2009-11-19 |
화이자 인코포레이티드 |
통증 치료에 유용한 n-(n-설폰일아미노메틸)사이클로프로판카복사마이드 유도체
|
US20080305161A1
(en)
*
|
2005-04-13 |
2008-12-11 |
Pfizer Inc |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
AU2006238747B2
(en)
|
2005-04-19 |
2012-04-26 |
King's College London |
Use
|
EP1874292A2
(en)
*
|
2005-04-24 |
2008-01-09 |
Wyeth |
Methods for modulating bladder function
|
AU2006242920A1
(en)
|
2005-05-04 |
2006-11-09 |
Pfizer Limited |
2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
|
AR053296A1
(es)
|
2005-05-23 |
2007-04-25 |
Cadbury Adams Usa Llc |
Composiciones que potencian el sabor y golosinas comestibles y productos de goma de mascar que los contienen
|
US7851005B2
(en)
|
2005-05-23 |
2010-12-14 |
Cadbury Adams Usa Llc |
Taste potentiator compositions and beverages containing same
|
US7851006B2
(en)
|
2005-05-23 |
2010-12-14 |
Cadbury Adams Usa Llc |
Taste potentiator compositions and beverages containing same
|
ES2277743B2
(es)
*
|
2005-06-02 |
2008-12-16 |
Universidade De Santiago De Compostela |
Nanoparticulas que comprenden quitosano y ciclodextrina.
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
MX2007015114A
(es)
|
2005-06-15 |
2008-02-15 |
Pfizer Ltd |
Arilpirazoles sustituidos.
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
AR054849A1
(es)
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
US20070221236A1
(en)
*
|
2005-10-05 |
2007-09-27 |
Cadbury Adams Usa Llc. |
Cooling compositions including menthyl esters
|
CN100503647C
(zh)
*
|
2005-11-02 |
2009-06-24 |
南京师范大学 |
羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
|
NZ568700A
(en)
*
|
2005-11-28 |
2012-03-30 |
Marinus Pharmaceuticals |
Solid stabilized particulate formulations comprising ganaxolone
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
CN101346073B
(zh)
*
|
2005-12-23 |
2013-02-13 |
卡夫食品环球品牌有限责任公司 |
提供基本上类似于由薄荷醇提供的感觉的组合物
|
CA2634873C
(en)
*
|
2005-12-23 |
2012-06-05 |
Cadbury Adams Usa Llc |
Compositions providing a heating sensation for oral or dermal delivery
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
TW200734334A
(en)
*
|
2006-01-13 |
2007-09-16 |
Wyeth Corp |
Treatment of substance abuse
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
AU2007230977A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Methods for treating cognitive and other disorders
|
AU2007229491A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Methods for treating cognitive and other disorders
|
TW200806300A
(en)
*
|
2006-03-24 |
2008-02-01 |
Wyeth Corp |
New therapeutic combinations for the treatment of depression
|
CA2644656A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Treatment of pain
|
BRPI0709164A2
(pt)
*
|
2006-03-24 |
2011-06-28 |
Wyeth Corp |
métodos para modulação da função da bexiga
|
KR100917809B1
(ko)
|
2006-05-22 |
2009-09-18 |
에스케이케미칼주식회사 |
우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
|
WO2008012538A2
(en)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Live vaccine strains of francisella
|
AU2007286651A1
(en)
|
2006-08-23 |
2008-02-28 |
Intellect Neurosciences Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
WO2008027557A2
(en)
*
|
2006-08-31 |
2008-03-06 |
Spherics, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
EP2380566A3
(en)
|
2006-09-15 |
2012-04-11 |
Stevia APS |
Treatment of insulin resistance or diseases associated with insulin resistance using steviol or isosteviol
|
MX2009000080A
(es)
|
2006-09-21 |
2009-01-23 |
Raqualia Pharma Inc |
Derivados de bencimidazol como inhibidores selectivos de la bomba de acido.
|
JP2010506839A
(ja)
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
乳光の低減を伴う方法および組成物
|
RS51647B
(en)
|
2006-10-18 |
2011-10-31 |
Pfizer Products Inc. |
BIARIL ETAR UREE UNITS
|
ATE520651T1
(de)
|
2006-10-23 |
2011-09-15 |
Pfizer |
Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
ES2555066T3
(es)
|
2006-11-17 |
2015-12-28 |
Supernus Pharmaceuticals, Inc. |
Formulaciones de liberación sostenida de topiramato
|
JP2010510988A
(ja)
*
|
2006-11-28 |
2010-04-08 |
マリナス ファーマシューティカルズ |
ナノ粒子製剤とその製造方法およびその利用
|
CN102218044A
(zh)
*
|
2006-12-04 |
2011-10-19 |
苏佩努斯制药公司 |
托吡酯的增强的立即释放制剂
|
JP4523073B2
(ja)
|
2007-02-06 |
2010-08-11 |
ファイザー・インク |
癌を治療するためのHSP−90阻害剤としての2−アミノ−5,7−ジヒドロ−6H−ピロロ[3,4−d]ピリミジン誘導体
|
PL2115126T3
(pl)
|
2007-03-02 |
2015-08-31 |
Wyeth Llc |
Zastosowanie miedzi i glutaminianu w hodowli komórkowej do wytwarzania polipeptydów
|
JP2010527986A
(ja)
*
|
2007-05-24 |
2010-08-19 |
ファイザー・リミテッド |
スピロ環状キナゾリン誘導体およびpde7阻害剤としてのその使用
|
TWI364290B
(en)
|
2007-05-25 |
2012-05-21 |
Ipsen Pharma Sas |
Melanocortin receptor ligands modifled with hydantoin
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
CN101861314B
(zh)
|
2007-09-05 |
2013-07-24 |
里格尔制药公司 |
N4-[(2,2-二氟-4h-苯并[1,4]*嗪-3-酮)-6-基]-5-氟-n2-[3-(甲基氨基羰基亚甲基氧基)苯基]-2,4-嘧啶二胺的1-羟基-2-萘甲酸盐
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
CA2706368A1
(en)
*
|
2007-11-20 |
2009-05-28 |
Cadbury Adams Usa Llc |
Dual coated confectionery product
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US20090275622A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Prasoona Linga |
Nizatidine formulations
|
US8242106B2
(en)
|
2008-08-01 |
2012-08-14 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
ES2378513T3
(es)
|
2008-08-06 |
2012-04-13 |
Pfizer Inc. |
Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
|
EP2163253B1
(en)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
|
JP5621148B2
(ja)
|
2008-11-21 |
2014-11-05 |
ラクオリア創薬株式会社 |
5−ht2b受容体拮抗活性を有する新規ピラゾール−3−カルボキサミド誘導体
|
KR101128450B1
(ko)
*
|
2008-12-11 |
2012-03-28 |
(주)바이오제닉스 |
안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물
|
US20120027722A1
(en)
|
2008-12-17 |
2012-02-02 |
Medical Research Council |
Hepatitis c virus combination therapy
|
NZ593473A
(en)
|
2009-01-12 |
2013-02-22 |
Pfizer Ltd |
Sulfonamide derivatives
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
ES2520165T3
(es)
|
2009-01-14 |
2014-11-11 |
Novacta Biosystems Limited |
Derivados de desoxiactagardina
|
TWI504610B
(zh)
|
2009-02-04 |
2015-10-21 |
Novacta Biosystems Ltd |
阿肽加定衍生物、其製備方法及其用途
|
AU2010223268B2
(en)
|
2009-03-12 |
2015-04-23 |
Haase Investments Gmbh |
Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
US20100291201A1
(en)
*
|
2009-05-14 |
2010-11-18 |
Cerovene, Inc. |
Coated pharmaceutical capsule dosage form
|
EP2435462A1
(en)
|
2009-05-29 |
2012-04-04 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
EP2266563A1
(en)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
RU2016108987A
(ru)
|
2009-08-18 |
2018-11-26 |
Вентиркс Фармасьютикалз, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
|
EP3225623A1
(en)
|
2009-08-18 |
2017-10-04 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
MX2012007402A
(es)
|
2009-12-23 |
2012-08-23 |
Takeda Pharmaceutical |
Pirrolidinonas heteroaromaticas fusionadas como inhibidores de tirosina cinasa esplenica (syk).
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
CA2789164A1
(en)
|
2010-02-02 |
2011-08-11 |
Novacta Biosystems Limited |
Lantibiotic salts
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
CA2789606A1
(en)
|
2010-02-25 |
2011-09-01 |
Pfizer Limited |
Peptide analogues as opioid receptor agonists
|
US8916593B2
(en)
|
2010-05-04 |
2014-12-23 |
Pfizer Inc. |
Alkoxy-substituted 2-aminopyridines as ALK inhibitors
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
CA2804173C
(en)
|
2010-07-09 |
2015-01-13 |
Pfizer Limited |
Sulfonamide nav1.7 inhibitors
|
EP2590957B1
(en)
|
2010-07-09 |
2014-11-12 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
WO2012004743A1
(en)
|
2010-07-09 |
2012-01-12 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
US9096500B2
(en)
|
2010-07-12 |
2015-08-04 |
Pfizer Limited |
Acyl sulfonamide compounds
|
WO2012007861A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
CA2800971A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
JP2013536165A
(ja)
|
2010-07-12 |
2013-09-19 |
ファイザー・リミテッド |
痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
|
JP2013532186A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
化合物
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
CN103154012B
(zh)
|
2010-08-24 |
2015-11-25 |
英皇创新有限公司 |
聚丙基醚亚胺的糖树状聚体
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
US9011912B2
(en)
|
2010-10-07 |
2015-04-21 |
Abon Pharmaceuticals, Llc |
Extended-release oral dosage forms for poorly soluble amine drugs
|
CN103429595B
(zh)
|
2010-11-15 |
2015-10-21 |
Viiv保健英国有限公司 |
Hiv复制的抑制剂
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
CN103384672B
(zh)
|
2011-02-25 |
2016-09-28 |
武田药品工业株式会社 |
N-取代的噁嗪并喋啶和噁嗪并喋啶酮
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
CN102139115B
(zh)
*
|
2011-03-30 |
2012-12-05 |
天津红日药业股份有限公司 |
阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
|
AP2013007159A0
(en)
|
2011-04-05 |
2013-10-31 |
Pfizer Ltd |
Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
|
JP5608873B2
(ja)
|
2011-05-18 |
2014-10-15 |
ラクオリア創薬株式会社 |
4−{[4−({[4−(2,2,2−トリフルオロエトキシ)−1,2−ベンズイソオキサゾール−3−イル]オキシ}メチル)ピペリジン−1−イル]メチル}−テトラヒドロ−2h−ピラン−4−カルボン酸の多形形態
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
JP6026525B2
(ja)
|
2011-06-22 |
2016-11-16 |
武田薬品工業株式会社 |
置換6−アザ−イソインドリン−1−オン誘導体
|
US8957025B2
(en)
|
2011-07-13 |
2015-02-17 |
Pfizer Inc. |
Enkephalin analogues
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
WO2013017136A1
(en)
|
2011-08-02 |
2013-02-07 |
Pensieve Biosciences Cyprus Limited |
Treatment of cognitive impairment
|
CA2842493A1
(en)
|
2011-08-02 |
2013-02-07 |
James Gail Christensen |
Crizotinib for use in the treatment of cancer
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
EA023375B1
(ru)
|
2011-10-26 |
2016-05-31 |
Пфайзер Лимитед |
Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
|
CA2853231C
(en)
|
2011-10-28 |
2020-08-04 |
Inhibitaxin Limited |
Pyridazine derivatives with autotaxin activity for use in therapy
|
US9085517B2
(en)
|
2011-12-15 |
2015-07-21 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
JP6067031B2
(ja)
|
2012-01-04 |
2017-01-25 |
ファイザー・リミテッドPfizer Limited |
N−アミノスルホニルベンズアミド
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
CA2861439C
(en)
|
2012-02-03 |
2016-07-12 |
Pfizer Inc. |
Benzimidazole and imidazopyridine derivatives as sodium channel modulators
|
TW201336527A
(zh)
*
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
EA026155B9
(ru)
|
2012-03-06 |
2017-06-30 |
Пфайзер Инк. |
Макроциклические производные для лечения пролиферативных заболеваний
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
EA201590199A1
(ru)
*
|
2012-07-12 |
2015-05-29 |
Санофи |
Противоопухолевая композиция, содержащая соединение 1-(6-{[6-(4-фторфенил)[1,2,4]триазоло[4,3-b]пиридазин-3-ил]сульфанил}-1,3-бензотиазол-2-ил)-3-(2-морфолин-4-илэтил)мочевины
|
IN2014KN02981A
(no)
*
|
2012-07-17 |
2015-05-08 |
Glaxosmithkline Llc |
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
US9533989B2
(en)
|
2012-09-18 |
2017-01-03 |
Ziarco Pharma Ltd. |
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
|
EP2900653A1
(en)
|
2012-09-28 |
2015-08-05 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
US20150218172A1
(en)
|
2012-10-04 |
2015-08-06 |
Pfizer Limited |
Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
US20150250785A1
(en)
|
2012-10-04 |
2015-09-10 |
Pfizer Limited |
Tropomyosin-Related Kinase Inhibitors
|
RU2617842C2
(ru)
|
2012-11-08 |
2017-04-28 |
Пфайзер Инк. |
Гетероароматические соединения и их применение в качестве допаминовых D1 лигандов
|
ES2652514T3
(es)
|
2012-11-08 |
2018-02-02 |
Pfizer Inc. |
Compuestos heteroaromáticos como ligandos de dopamina D1
|
JP5903681B2
(ja)
|
2012-11-21 |
2016-04-13 |
ラクオリア創薬株式会社 |
多形形態
|
MX368898B
(es)
|
2012-12-03 |
2019-10-21 |
Pfizer |
Moduladores selectivos del receptor de androgenos novedosos.
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
WO2014128588A1
(en)
|
2013-02-21 |
2014-08-28 |
Pfizer Inc. |
Solid forms of a selective cdk4/6 inhibitor
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
EP2784083A1
(en)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
|
EP2792360A1
(en)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
ES2729630T3
(es)
|
2013-06-27 |
2019-11-05 |
Pfizer |
Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
|
KR20160029125A
(ko)
|
2013-07-08 |
2016-03-14 |
애브비 인코포레이티드 |
아트라센탄을 포함하는 안정화된 약제학적 용량형
|
CA2915445C
(en)
*
|
2013-07-19 |
2024-04-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
CA2934010A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
UY35945A
(es)
|
2014-01-09 |
2015-08-31 |
Takeda Pharmaceutical |
Derivados de azaindol
|
WO2015157509A1
(en)
*
|
2014-04-10 |
2015-10-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating opioid receptor associated diseases
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
AU2015249496A1
(en)
|
2014-04-25 |
2016-09-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
CA2946475A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EP3137454A1
(en)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
JP6564394B2
(ja)
|
2014-04-28 |
2019-08-21 |
ファイザー・インク |
複素環式化合物およびそのドーパミンd1リガンドとしての使用
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
EA201650029A1
(ru)
|
2014-05-14 |
2017-09-29 |
Пфайзер Инк. |
Пиразолопиридины и пиразолопиримидины
|
PL3143019T3
(pl)
|
2014-05-15 |
2021-03-22 |
Pfizer Inc. |
Krystaliczna postać 6-[(4R)-4-metylo-1,2-dioksydo-1,2,6-tiadiazynan-2-ylo]izochinolino-1-karbonitrylu
|
WO2015178020A1
(en)
|
2014-05-20 |
2015-11-26 |
Raqualia Pharma Inc. |
Benzisoxazole derivative salt
|
JP2017516803A
(ja)
|
2014-05-30 |
2017-06-22 |
ファイザー・インク |
ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
CA2951497C
(en)
|
2014-06-12 |
2019-04-09 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the gabaa receptor activity
|
AP2016009605A0
(en)
|
2014-06-17 |
2016-12-31 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
BR112017015536B1
(pt)
|
2015-01-22 |
2021-05-18 |
Phytoplant Research S.L |
métodos de purificação de canabinoides
|
ES2764840T3
(es)
|
2015-01-28 |
2020-06-04 |
Univ Bordeaux |
Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
|
JP6584521B2
(ja)
|
2015-02-24 |
2019-10-02 |
ファイザー・インク |
抗がん剤として有用な置換ヌクレオシド誘導体
|
CA2979527A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
|
JP6832914B2
(ja)
|
2015-07-31 |
2021-02-24 |
ファイザー・インク |
Magl阻害薬としての1,1,1−トリフルオロ−3−ヒドロキシプロパン−2−イルカルバマート誘導体および1,1,1−トリフルオロ−4−ヒドロキシブタン−2−イルカルバマート誘導体
|
US20180193335A1
(en)
*
|
2015-10-12 |
2018-07-12 |
Vikash J. BHAGWANDIN |
Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
|
CA3007595C
(en)
|
2015-12-10 |
2020-08-25 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
PL3394045T3
(pl)
|
2015-12-24 |
2021-09-27 |
Takeda Pharmaceutical Company Limited |
Kokryształ, sposób jego wytwarzania i lek zawierający kokryształ
|
TWI726968B
(zh)
|
2016-01-07 |
2021-05-11 |
開曼群島商Cs醫藥技術公司 |
Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
MX2018008653A
(es)
|
2016-01-15 |
2018-12-10 |
Pfizer |
Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
|
JP7112957B2
(ja)
|
2016-03-09 |
2022-08-04 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
腫瘍細胞懸濁培養及び関連方法
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
MX2019001153A
(es)
|
2016-07-29 |
2019-06-10 |
Pfizer |
Peptidos ciclicos como antagonistas del receptor c5a.
|
WO2018031748A1
(en)
|
2016-08-11 |
2018-02-15 |
Ovid Therapeutics Inc. |
Methods and compositions for treatment of epileptic disorders
|
BR112019002610A2
(pt)
|
2016-08-15 |
2019-07-02 |
Pfizer |
piridopirimidinonas inibidoras de cdk2/4/6
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
JP7273723B2
(ja)
|
2016-12-20 |
2023-05-15 |
オリゴメリックス インコーポレイテッド |
タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
|
SG11201906417RA
(en)
|
2017-01-20 |
2019-08-27 |
Pfizer |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
BR112019014099A2
(pt)
|
2017-01-23 |
2020-02-11 |
Pfizer Inc. |
Compostos espiro-heterocíclico como inibidores de magl
|
EP3600312B1
(en)
|
2017-03-26 |
2023-05-17 |
Takeda Pharmaceutical Company Limited |
Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
WO2018234808A1
(en)
|
2017-06-22 |
2018-12-27 |
Curadev Pharma Limited |
MODULATORS WITH SMALL MOLECULES OF STING HUMAIN
|
EP3644977A1
(en)
*
|
2017-06-30 |
2020-05-06 |
Industrial Technology Research Institute |
Method for treating an autoimmune neurological disease and/or neurodegenerative disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form
|
MX2020002303A
(es)
|
2017-08-30 |
2020-09-10 |
Beijing Xuanyi Pharmasciences Co Ltd |
Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
|
MA50245A
(fr)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals Inc |
Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
AU2019211188A1
(en)
|
2018-01-29 |
2020-07-30 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
TWI741268B
(zh)
|
2018-03-15 |
2021-10-01 |
美商輝瑞股份有限公司 |
干擾素基因刺激劑(sting)的環戊烷為主體之調節劑
|
WO2019180072A1
(en)
|
2018-03-22 |
2019-09-26 |
Bayer Pharma Aktiengesellschaft |
Parenteral pharmaceutical composition comprising neladenoson bialanate
|
EP3784664A1
(en)
|
2018-04-26 |
2021-03-03 |
Pfizer Inc |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
WO2020016710A1
(en)
|
2018-07-19 |
2020-01-23 |
Pfizer Inc. |
Heterocyclic spiro compounds as magl inhibitors
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
CA3121139A1
(en)
|
2018-11-29 |
2020-06-04 |
Pfizer Inc. |
Pyrazoles as modulators of hemoglobin
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
TWI732431B
(zh)
|
2019-01-23 |
2021-07-01 |
美商輝瑞股份有限公司 |
多形體
|
BR112021012635A2
(pt)
|
2019-01-31 |
2021-12-14 |
Pfizer |
Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
|
WO2020198053A1
(en)
|
2019-03-22 |
2020-10-01 |
Takeda Pharmaceutical Company Limited |
2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
|
MA55804A
(fr)
|
2019-04-29 |
2022-04-06 |
Solent Therapeutics Llc |
Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
CN114269720A
(zh)
|
2019-07-25 |
2022-04-01 |
库拉德夫制药私人有限公司 |
乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
|
CA3145923A1
(en)
|
2019-08-05 |
2021-02-11 |
David Czekai |
Ganaxolone for use in treatment of status epilepticus
|
AU2020348675A1
(en)
|
2019-09-16 |
2022-04-14 |
Takeda Pharmaceutical Company Limited |
Azole-fused pyridazin-3(2H)-one derivatives
|
WO2021059136A1
(en)
|
2019-09-25 |
2021-04-01 |
Pfizer Inc. |
Polyheterocyclic modulators of sting (stimulator of interferon genes)
|
CN110538094B
(zh)
*
|
2019-09-27 |
2022-01-18 |
华南理工大学 |
一种均相亲水和多维稳定的紫檀芪@环糊精包合物及其制备方法
|
IL293525A
(en)
|
2019-12-06 |
2022-08-01 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in the treatment of multiple sclerosis complex
|
CN110898015A
(zh)
*
|
2019-12-31 |
2020-03-24 |
上海汉维生物医药科技有限公司 |
一种伊曲康唑制剂的制备方法
|
AU2021219370A1
(en)
|
2020-02-12 |
2022-08-25 |
Curadev Pharma Pvt. Ltd. |
Small molecule STING antagonists
|
NL2025092B1
(en)
*
|
2020-03-10 |
2021-10-19 |
Seranovo Holding B V |
Solid deep eutectic solvent formulation platform
|
US20230137547A1
(en)
|
2020-03-10 |
2023-05-04 |
Seranovo Holding B.V. |
Solid Deep Eutectic Solvent Formulation Platform
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
EP4121417A4
(en)
*
|
2020-05-01 |
2023-08-09 |
University Of Southern California |
CYCLODEXTRIN-BASED ANTIMICROBIAL THERAPY
|
CR20220548A
(es)
|
2020-05-01 |
2022-12-12 |
Pfizer |
Compuestos de azalactama como inhibidores de hpk1
|
CN115515933A
(zh)
|
2020-05-04 |
2022-12-23 |
武田药品工业株式会社 |
经管腔作用的n-(哌啶-4-基)苯甲酰胺衍生物
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
US20220168272A1
(en)
*
|
2021-02-22 |
2022-06-02 |
Gholamhossein Yousefi |
Preparation of soluble form of carvedilol
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
CN113081989B
(zh)
*
|
2021-03-29 |
2022-10-21 |
海南普利制药股份有限公司 |
别嘌醇缓释片剂
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
WO2022207673A1
(en)
|
2021-03-31 |
2022-10-06 |
Sevenless Therapeutics Limited |
Sos1 inhibitors and ras inhibitors for use in the treatment of pain
|
CA3214567A1
(en)
|
2021-04-07 |
2022-10-13 |
Martin AMBLER |
2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
|
CR20230604A
(es)
|
2021-06-26 |
2024-02-19 |
Array Biopharma Inc |
Inhibidores de mutación de her2
|
TW202321232A
(zh)
|
2021-08-11 |
2023-06-01 |
印度商裘拉德製藥私人有限公司 |
小分子sting拮抗劑
|
CN118019738A
(zh)
|
2021-08-11 |
2024-05-10 |
库拉德夫制药私人有限公司 |
作为sting拮抗剂的小分子脲衍生物
|
KR20240110971A
(ko)
|
2021-12-01 |
2024-07-16 |
푼다시온 델 섹토르 푸블리코 에스타탈 센트로 나시오날 데 인베스티가시오네스 온콜로지카스 카를로스 3 (에프.에스.피 씨엔아이오) |
화합물
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
AR129012A1
(es)
|
2022-04-07 |
2024-07-03 |
Takeda Pharmaceuticals Co |
Derivados de piridazina fusionados
|
US20240109915A1
(en)
|
2022-07-29 |
2024-04-04 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
CN115487080A
(zh)
*
|
2022-09-23 |
2022-12-20 |
山东博科医用材料有限公司 |
补骨脂酚微胶囊及其制备方法
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|
WO2024105363A1
(en)
|
2022-11-15 |
2024-05-23 |
Curadev Pharma Ltd |
Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
|
WO2024157205A1
(en)
|
2023-01-26 |
2024-08-02 |
Takeda Pharmaceutical Company Limited |
1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
|